课题基金 / 基金详情

项目摘要

项目成果

Bing Zhang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The Cancer Genome Atlas (TCGA) initiative, by generating comprehensive genomic characterization of diverse human cancers, poses the critical question of how genomic variation translates to cancer. Genomic abnormalities are thought to drive cancer phenotypes through their effects on proteins and proteomes, which can be analyzed by systematic application of new proteomic technologies. The National Cancer Institute (NCI) Clinical Proteomic Technology Assessment for Cancer (CPTAC) initiative has implemented standardized technology platforms in a biomarker development pipeline and, as one of the initial 5 CPTAC programs, we have made a major contribution to this effort. We have already pioneered this pipeline for cancer biomarker development through the Jim Ayers Institute for Precancer Detection and Diagnosis, a unique initiative established in the Vanderbilt-lngram Cancer Center. This application proposes the Vanderbilt Proteome Characterization Center (Vanderbilt PCC) built on the expertise and infrastructure of the Ayers Institute. The overall goal of the Vanderbilt PCC is to integrate genomic information with proteomic technologies to discover and verify protein biomarkers for cancer. To analyze genomically characterized tumor tissue biospecimens from the TCGA program, we will apply standardized liquid chromatography-tandem mass spectrometry (LC-MS/MS) and liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) platforms. These analyses will encompass global protein expression changes and changes in phosphorylated and acetylated proteins that regulate signaling networks in cancer. The Vanderbilt PCC will integrate TCGA-derived genomic data and other relevant information into the discovery process and develop systematic approaches to prioritize biomarker candidates. We will verify biomarker candidates in clinically relevant cohorts with standardized, targeted analyses. We will also advance technologies for assessment of signaling networks and functional subproteomes, the integration of genomic and proteomic data and the evaluation of analytical system performance. The Vanderbilt PCC brings to the CPTC network a fully integrated program with expertise in all of the critical areas specified by the RFA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Illuminating understudied druggable proteins using pan-cancer proteogenomics data
  • 批准号:
    10449905
  • 项目类别:
  • 资助金额:
    $47.52万
  • 财政年份:
    2022
  • 负责人:
    Bing Zhang
  • 依托单位:
iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC
  • 批准号:
    10440591
  • 项目类别:
  • 资助金额:
    $89.67万
  • 财政年份:
    2022
  • 负责人:
    Bing Zhang
  • 依托单位:
iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC
  • 批准号:
    10632121
  • 项目类别:
  • 资助金额:
    $86.41万
  • 财政年份:
    2022
  • 负责人:
    Bing Zhang
  • 依托单位:
Illuminating understudied druggable proteins using pan-cancer proteogenomics data
  • 批准号:
    10671574
  • 项目类别:
  • 资助金额:
    $48.0万
  • 财政年份:
    2022
  • 负责人:
    Bing Zhang
  • 依托单位:
海外基金